{"id":"W4283702633","doi":"10.1136/annrheumdis-2022-eular.1377","title":"AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Queen's University","funders":"AbbVie; Bristol-Myers Squibb","keywords":"Medicine; Psoriasis; Placebo; Apremilast; Internal medicine; Psoriatic arthritis; Psoriasis Area and Severity Index; Clinical trial; Gastroenterology; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00103709,0.000884075,0.001757496,0.0002764582,0.000278984,0.0007598042,0.0004051143,0.0007139314,0.002232209],"category_scores_gemma":[0.0004712071,0.0002623468,0.001110092,0.0002385683,0.0003537326,0.0006087315,0.00017392,0.002198112,0.0008613319],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004507038,"about_ca_system_score_gemma":0.0004727866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009763894,"about_ca_topic_score_gemma":0.003287595,"domain_scores_codex":[0.9997317,0.00008679566,0.00001535391,0.00003833837,0.00004925488,0.00007857587],"domain_scores_gemma":[0.9996679,0.0000736569,0.00006236627,0.00002291362,0.00003179166,0.000141352],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2950743,0.01974657,0.005844001,0.002116153,0.002732026,0.0003781104,0.0002731413,0.005401671,0.07597096,0.0004570045,0.01978089,0.5722252],"study_design_scores_gemma":[0.4685539,0.3923256,0.08353857,0.0003078528,0.002453381,0.002060641,0.0002278558,0.006686086,0.01775543,0.000856517,0.02502982,0.0002043842],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9712728,0.01982106,0.0007336198,0.0007737197,0.0002362121,0.0004648115,0.001332269,0.0003543046,0.005011304],"genre_scores_gemma":[0.9826245,0.008639955,0.0008063741,0.0008020218,0.0001667109,0.0002566084,0.002573,0.00005490418,0.004075884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002232209,"threshold_uncertainty_score":0.007467449,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08045805314873049,"score_gpt":0.3275665331738446,"score_spread":0.2471084800251141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}